Pitcairn’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Pitcairn’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-14,443	Closed	-$260K	–	593
2017 Q4	$260K	Buy	14,443 +527	+4%	+$6.49K	0.03%	424
2017 Q3	$164K	Sell	13,916 -169	-1%	-$1.9K	0.02%	485
2017 Q2	$148K	Sell	14,085 -179	-1%	-$1.82K	0.02%	465
2017 Q1	$157K	Sell	14,264 -589	-4%	-$6.84K	0.02%	477
2016 Q4	$201K	Buy	+14,853	New	+$207K	0.02%	487

Other funds holding SCMP

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AIM

Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Pitcairn's SCMP Position: Q1 2018 in Review

Pitcairn sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 14,443 shares — an estimated $260K sold.

Pitcairn first reported a position in SCMP in Q4 2016 and held it in 5 quarters. The position peaked at $260K in Q4 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

Pitcairn reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Pitcairn sold 14,443 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $260K.
Pitcairn first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2016 and held it in 5 quarters.
Pitcairn's Sucampo Pharmaceuticals, Inc. position peaked at $260K in Q4 2017.
3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Pitcairn's 13F filing for Q1 2018, filed 11 May 2018.